Anthracyclines, HER2, and TOP2A: the verdict-Reference-Cited by-同舟云学术

Anthracyclines, HER2, and TOP2A: the verdict

Published:2011-11 Issue:12 Volume:12 Page:1084-1085
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Bonnefoi Hervé R

Publisher

Elsevier BV

Subject

Oncology

Reference11 articles.

1. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials;Gennari;J Natl Cancer Inst,2008

2. HER2/neu in systemic therapy for women with breast cancer: a systematic review;Dhesy-Thind;Breast Cancer Res Treat,2008

3. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial;Bartlett;J Clin Oncol,2008

4. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy;O'Malley;J Natl Cancer Inst,2009

5. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data;Di Leo;Lancet Oncol,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: a mechanism-based pharmacokinetic/pharmacodynamic modeling approach;Frontiers in Pharmacology;2023-10-19

2. Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials;Clinical Cancer Research;2021-10-06

3. Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?;The Oncologist;2018-08-17

4. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells;British Journal of Pharmacology;2015-02-27

5. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms;BMC Cancer;2014-11-18